| Consultant360

Research Summaries

FDA Approval

FDA Approval

FDA Approves Gedatolisib After Endocrine Therapy Progression in Advanced Breast Cancer

07/17/2026

Anthony Calabro, MA

The FDA approved gedatolisib with fulvestrant, with or without palbociclib, for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected after...

07/17/2026

Research Summary

Woman with clipboard holding someone's hands

Research Summary

Danish Primary Care Trials Find Collaborative Care Improves Long-Term Depression Outcomes Versus Consultation Liaison

07/17/2026

Kate Young

In two pragmatic randomized trials conducted in the Capital Region of Denmark, investigators compared collaborative care with consultation liaison in general practice to assess whether greater involvement...

07/17/2026

FDA APPROVAL

FDA APPROVAL

FDA Approves Lipfendra as First Oral PCSK9 Inhibitor for Adults With High Cholesterol

07/16/2026

Anthony Calabro, MA

The FDA approval provides physicians with a once-daily oral PCSK9 inhibitor option to reduce LDL-C in adults with high cholesterol, including those with heterozygous familial hypercholesterolemia.

07/16/2026

Research Summary

Research Summary

Marstacimab Reduces Bleeding Rates in Adolescent, Adult Men With Hemophilia A/B With Inhibitors

07/16/2026

Ashton L. Stahl

A phase 3 trial evaluated weekly marstacimab prophylaxis in adolescents and adults with hemophilia A or B with inhibitors.

07/16/2026

Research Summary

Research Summary

Phase 3 Trial: Oral Infigratinib Improves Annualized Height Velocity in Children With Achondroplasia

07/16/2026

Anthony Calabro, MA

In a phase 3 RCT of children aged 3 to 17 years with achondroplasia, once-daily oral infigratinib significantly increased annualized height velocity vs placebo at 52 weeks.

07/16/2026

July 2026

Current Issue

July 2026